Connect with us

Micro Cap Insider

Nsav Holding Inc (OTC: NSAV) Powerhouse Comeback as Emerging Crypto Operator Expands on VirtuaBroker, & SBCDF Investments by Launching Fully Regulated Cryptocurrency Exchange

Published

2 years ago

on

Nsav Holding Inc (OTC: NSAV) continues to move steadily higher with power in recent days since a brief dip below a penny after the Company reported it plans to launch a fully regulated Cryptocurrency Exchange on August 9. Currently NSAV is under heavy accumulation and moving up quickly with momentum. NSAV is emerging as among the most actively searched and talked about stocks in small caps regularly trading over $5 million in dollar volume per day. NSAV is looking to blaze a path along the likes of Enzolytics or Tesoro and break out into a whole new dimension – Tesoro went to multi dollars – a break over $0.0697 and its blue skies ahead. 

NSAV is making big moves in the crypto space; the Company’s management team and its partners are pioneers in the Digital Asset and Blockchain industry. The team is led by NSAV Director, Mr. Yuen Wong. Mr. Wong CEO of LABS Group Limited and Managing Partner at Bitmart Cryptocurrency Exchange. Earlier this year the Company acquired Swiss Cryptocurrency Trading Platform; VirtuaBroker Ltd., with offices in London and Barcelona.  The Company also recently acquired a major 25% stake in SBCDF Investment, Inc. which will soon launch its STUX (SBC Token Unix X). NSAV also recently launched the worlds first NFT (Non-Fungible Token) resort project. The Flagship NFT resort, located near the historic and world- renowned tourist and cultural destination of Bali, Indonesia, will be fractionalized into 365 RTS (Rewarding Timeshare)-NFTs. NSAV is also launching a fully regulated Cryptocurrency Exchange. The Company will own 100% of the exchange and it will carry the NSAV brand name which is expected to go live on August 9. 

Nsav Holding Inc (OTC: NSAV) vision is the establishment of a fully integrated technology company that provides turnkey technological solutions to the cryptocurrency, blockchain and digital asset industries. Over time, the Company plans to provide a wide range of services such as software solutions, e-commerce, advisory services, financial services and information technology. The management of NSAV and its partners are pioneers in the Digital Asset and Blockchain industry. The team is led by NSAV Director, Mr. Yuen Wong. Mr. Wong is also the CEO of LABS Group Limited https://labsgroup.io, the world’s first end to end Blockchain powered real estate investment ecosystem and powered by the LABS ecosystem token through decentralized finance (DeFi) and governance. Mr. Wong is also a Managing Partner at Bitmart Cryptocurrency Exchange  https://www.bitmart.com. BitMart is a premier global digital asset trading platform with over 2 million users worldwide and ranked among the top crypto exchanges on CoinMarketCap. Bitmart’s platform supports over 220 cryptocurrencies and has a 24 hour trading volume of approximately $2 Billion.” 

NSAV recently closed the acquisition of VirtuaBroker Ltd, a Swiss Cryptocurrency Trading Platform with offices in London and Barcelona. VirtuaBroker, whose platform is based on Artificial Intelligence (AI), offers a full range of trading services, such as portfolio management, price search function, and much more. Their platform supports nearly all the major cryptocurrency exchanges, including Coinbase ($2 billion Revenue in 2019), Binance ($4.2 billion Crypto Assets), Bitfinex ($404 million Net Profits in 2018) and Kraken ($1.25 billion estimated Annual Revenues). With the recent announcements of Tesla and Mastercard joining the Crypto revolution, the management of NSAV believes that this will be a major step in fulfilling the Company’s ambition of being a leading player in the over $200 billion annual cryptocurrency market. The Company plans to Roll Out the Global Launch of VirtuaBroker at the end of March. Terms of the deal were not disclosed. VirtuaBroker’s AI Cryptocurrency Trading Platform is your 24/7 account manager. Customers will save time and be provided with an optimal trading experience. The AI Platform allows users to optimize the trades that they require according to their selected objectives and allows them to make decisions based on market sentiment data. VirtuaBroker’s security policy is its pillar and is based on a five-tiered security stack, including Fraud Protection, Privacy Protection, Encryption and Network Defenses, VirtuaBroker Security ID and Security Alerts. 

NSAV also acquired a major 25% stake in SBCDF Investment, Inc. which will soon launch its STUX (SBC Token Unix X). The STUX token will be marketed via all the major social channels such as, Reddit, Discord, Telegram, Twitter and Medium. To complete the transaction, NSAV will issue 500 million restricted Preferred B shares, which are valued at an estimated $15 million. NSAV retains the option to purchase an additional 25% under the same terms. SBC Financial Group, Inc. will structure the transaction and advise on the token launch and strategy related to how the token will drive the NSAV ecosystem.  

To Find out the inside Scoop on NSAV Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

NSAV

In June the Company reported its prized stake holding, VirtuaBroker has launched the world’s first sustainable crypto platform. The growing concern of the environmental impact of cryptocurrencies, most recently expressed by TESLA CEO, Elon Musk, is now being addressed by Virtuabroker. Virtuabroker has deployed sustainability technology, powered by Dublin based, Nozama Tech onto its platform to enable sustainable trading, driven by the company’s Artificial Intelligence (AI) powered, 24/7 multi-exchange cryptocurrency trading platform. Sustainable crypto trading is another element of the already innovative technology Virtuabroker has developed for its customers, in order to save time and be provided with an optimal trading experience. Nozama Techs sustainability technology enables Virtuabroker to track the CO 2 footprint of every crypto transaction within the Proof of Work and Proof of Stake protocols and also offers micro-offsetting functionalities. The Carbon Credits for those offsetting activities mainly come from projects related to hyperquestration, land-regeneration, solar energy, and/or plastic recycling projects (Gold Standard and/or VERRA), which will be audited by validation/verification bodies (VVBs). 

NSAV recently launched the world’s first NFT (Non-Fungible Token) resort project. The Flagship NFT resort, located near the historic and world- renowned tourist and cultural destination of Bali, Indonesia, will be fractionalized into 365 RTS (Rewarding Timeshare)-NFTs. Each RTS-NFT represents a specific day and staying right in the Property. NFT holders share the property profit with a guaranteed minimum 10% return per year, in the first 2 years, based on the nominal price. In addition, NFT holders can easily trade their RTS-NFTs on the Refinable Marketplace https://refinable.co/ based on Binance Smart Chain (BSC) https://www.binance.org/en/smartChain and Ethereum. The NFTs will be sold via an auction beginning July 15. The management of NSAV believes that now is the perfect time to enter the NFT market, given explosive growth and expanding applicability of the NFT marketplace sector. According to NonFungible.com, over $2 billion was spent on non-fungible tokens during the first quarter of 2021 an increase of about 2,100% from Q4 2020 and already far surpassing the $250 million NFT market in 2020. 

Earlier this month NSAV announced its intention to launch a fully regulated Cryptocurrency Exchange. The Company will own 100% of the exchange and it will carry the NSAV brand name. NSAV is up big after the Company announced its Cryptocurrency Exchange will launch on August 9, 2021. The project is well under way and additional details and updates will be announced on a weekly basis. NSAV has added a countdown timer to its corporate website, https://nsavholdinginc.com/, in order to keep shareholders apprised of exactly how much time remains until the official launch of the Cryptocurrency Exchange. 

For more on NSAV Subscribe Right Now!

Nsav Holding Inc continues to move steadily higher with power in recent days since a brief dip below a penny after the Company reported it plans to launch a fully regulated Cryptocurrency Exchange on August 9. Currently NSAV is under heavy accumulation and moving up quickly with momentum. NSAV is emerging as among the most actively searched and talked about stocks in small caps regularly trading over $5 million in dollar volume per day. NSAV is looking to blaze a path along the likes of Enzolytics or Tesoro and break out into a whole new dimension – Tesoro went to multi dollars – a break over $0.0697 and its blue skies ahead. NSAV is making big moves in the crypto space; the Company’s management team and its partners are pioneers in the Digital Asset and Blockchain industry. The team is led by NSAV Director, Mr. Yuen Wong. Mr. Wong CEO of LABS Group Limited and Managing Partner at Bitmart Cryptocurrency Exchange. Earlier this year the Company acquired Swiss Cryptocurrency Trading Platform; VirtuaBroker Ltd., with offices in London and Barcelona.  The Company also recently acquired a major 25% stake in SBCDF Investment, Inc. which will soon launch its STUX (SBC Token Unix X). NSAV also recently launched the worlds first NFT (Non-Fungible Token) resort project. The Flagship NFT resort, located near the historic and world- renowned tourist and cultural destination of Bali, Indonesia, will be fractionalized into 365 RTS (Rewarding Timeshare)-NFTs. NSAV is also launching a fully regulated Cryptocurrency Exchange. The Company will own 100% of the exchange and it will carry the NSAV brand name which is expected to go live on August 9. We will be updating on NSAV when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with NSAV.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in NSAV either long or short and we have not been compensated for this article.

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Featured

T2 Biosystems (NASDAQ: TTOO) Breaks Ground: FDA Clearance, Market Trends, and Healthcare Impact

Published

3 days ago

on

September 29, 2023

By

Shares of T2 Biosystems (NASDAQ:TTOO) are soaring up over 20% today on the heels of receiving a 510(k) clearance for its T2Biothreat from the FDA. This unique test directly detects six biothreat pathogens from a blood sample.

Spotting Biothreats Faster:

T2Biothreat Panel is a game-changer, being the first and only FDA-approved product that can spot these critical biothreat pathogens simultaneously. T2 Biosystems proudly stands as the first U.S. company to achieve this milestone, reshaping the field of biothreat detection.

Big Investor Sells:

Interestingly while celebrating this achievement, a significant investor, CR Group (CRG), decided to sell off a substantial chunk of shares. This sell-off, totaling 24.81 million shares, took place between Sept. 20 and Sept. 26. The timing of this sell-off alongside the FDA clearance raises some eyebrows.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

New CDC Guidelines:

Regardless of CR Group selling, there still appears to be a massive opportunity according to many retail investors. Following new CDC guidelines, the U.S. government now mandates that all hospitals in the country must adopt rapid testing protocols to combat the sepsis pandemic by 2026, or risk losing Medicare funding.

Buying opportunity of the year!!! Update
byu/den1183 inTTOOstock

T2 Biosystems stands as the exclusive FDA-cleared product capable of achieving 100% accurate sepsis detection within 3 to 5 hours. Anticipating widespread adoption of T2 instruments in hospitals, the CEO foresees significant revenue generation, potentially reaching $1.3 billion annually, given the mandate.

This development drastically alters the landscape, potentially influencing the stock’s trajectory positively. With the ongoing surge in manufacturing hires and likely acceleration in orders, coupled with potential government contracts or international sales, many beleive T2 Biosystems presents an undervalued opportunity for investors.

What Borrowing Costs Tell Us:

Another interesting indicator to look at is the cost to borrow (CTB) fee. In terms of TTOO’s case, the stock has seen a massive surge in CTB fees, indicating a high demand from short sellers. When compared to the average CTB fee for other stocks, it’s pretty drastic. While this is typically not a very positive sign, retail investors seem to be buzzing with interest, given there also could be a potential short squeeze if enough buying comes in to trap the shorts.

Better News for Patients:

But let’s not forget the real impact and that’s what TTOO can do for patients. @ChengKeki a user from Twitter also shared an article about Butler Memorial Hospital and their approach to Sepsis. The hospital came up with a 2 step approach to expedite patient care.  They’re utilizing the Beckman Coulter automation line to identify changes in a person’s blood cells that might indicate the development of sepsis. Which apparently has only been used in Europe and they’re the first in the US with the technology. Then shortly after, they use T2 Biosystems panels that as you know, quicken the process from 36 hours, to just 3-5 hours.

Catching sepsis quickly is crucial because it’s a life-threatening condition that rapidly progresses throughout your body and can lead to death if not promptly diagnosed and treated. Sepsis occurs when the body responds improperly to an infection, causing widespread inflammation and potentially damages multiple organ systems. Early detection allows for immediate medical intervention.

Conclusion:

T2 Biosystems is hitting major milestones, not only in the market but in improving critical healthcare processes. The company is also a major hit with retail investors and continues to trade an astronomical amount of shares daily, the current average is ~115M shares. The FDA approval and its implications, along with the positive shift in sepsis diagnosis, showcase T2 Biosystems’ growing role in healthcare. Keep an eye on how this progresses—it’s exciting for both investors and patients alike.

We will update you on TTOO when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Picture by jarmoluk from Pixabay

 

Continue Reading

BioPharma

Organogenesis (NASDAQ: ORGO): Latest Developments and Future Growth Prospects

Published

4 days ago

on

September 28, 2023

By

Organogenesis Holdings (NASDAQ: ORGO), a top regenerative medicine company dedicated to advanced wound care, surgical, and sports medicine solutions, gains over 30% during intraday trading and after hours combined after their latest release. According to the release, three Medicare Administrative Contractors (MACs) decided to withdraw certain coverage rules that were meant to start on October 1. These rules related to products for treating diabetic foot ulcers (DFU) and venous leg ulcers (VLU).

More Background:

Organogenesis serves a range of clients, from hospitals and wound care centers to doctors’ offices. The MACs’ initial rules, set on August 9, caused concern. They specified that covered products must be particular types of skin substitutes. Unfortunately, this excluded five products from Organogenesis, impacting their financial outlook.

Fast forward, the MACs pulled back these rules just in time, preventing potential harm to Organogenesis. Even before these rules, the company was facing challenges. In the second quarter, revenue was slightly down compared to the same period last year. Despite this, the company is doing better than the previous year in a six-month comparison.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Gary S. Gillheeney, Sr., the head of Organogenesis, expressed deep gratitude for the MACs and the Centers for Medicare & Medicaid Services (CMS). He praised their thoughtful consideration of stakeholder concerns and putting patients first. This decision will positively affect the lives of many.

He also thanked the stakeholders, including doctors, patient advocacy groups, and various associations. Their unified support played a vital role in challenging these rules, considering the potential harm they could cause patients. Their advocacy shed light on the possible negative health outcomes and treatment disparities, especially for those with higher rates of diabetes and related conditions. Their collective efforts made a significant difference.

We will update you on ORGO when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by Parentingupstream from Pixabay

Continue Reading

Featured

Femasys’ (NASDAQ: FEMY) FemaSeed Receives FDA Nod: A Game-Changer for Infertility Treatment

Published

6 days ago

on

September 26, 2023

By

Femasys Inc. (NASDAQ: FEMY) hit a massive milestone and saw shares soar by a whopping 346%. The reason? The United States Food and Drug Administration (FDA) has given the thumbs up for the commercialization of FemaSeed, a game-changing option for artificial insemination aiming to boost the natural fertilization process.

FemaSeed:

It’s a breakthrough treatment for infertility, designed to carry sperm right to where conception happens in a woman’s fallopian tube. This breakthrough could change the game in infertility treatments by offering a less invasive option compared to heavy hitters like in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI), potentially reducing the risk of complications during the procedure.

Kathy Lee-Sepsick, Femasys’ founder and CEO, is beyond excited about the FDA’s green light for FemaSeed. She highlights how this could be a game-changer in providing infertility treatments that are less of a burden. The FDA clearance is a testament to successful teamwork with the FDA and a major step forward in making this new technology available to those struggling with infertility.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

The rising numbers of infertility cases in the United States (about 10 million women, as per the Center for Disease Control) show how crucial it is to have accessible and effective infertility treatments. FemaSeed is ready to meet this need by offering an affordable and efficient option for those dealing with infertility.

Here’s an interesting tidbit: FemaSeed works in harmony with FemVue, Femasys’ FDA-cleared diagnostic device. FemVue lets doctors perform an in-office ultrasound assessment of the fallopian tubes, helping diagnose infertility even before going for FemaSeed.

But wait, there’s more! Femasys isn’t just about FemaSeed. They’re also charging ahead with FemBloc, their lead candidate for permanent birth control in late-stage clinical development. Their commitment is to provide accessible solutions for women’s health, covering unmet needs with a range of innovative in-office products.

In a nutshell, Femasys is all about empowering women and couples facing fertility challenges. Their aim? To provide cost-effective and less invasive infertility treatments, backed by innovative diagnostic solutions. With this FDA clearance for FemaSeed, Femasys is a step closer to achieving this mission and leaving a lasting impact in the realm of women’s healthcare.

We will update you on FEMY when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by DigitalMarketingAgency from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.